The new NCI screen and its implications for clinical evaluation
- PMID: 7355249
- DOI: 10.1007/978-3-642-81392-4_2
The new NCI screen and its implications for clinical evaluation
Similar articles
-
A prospective screening program: current screening and its status.Recent Results Cancer Res. 1981;76:176-91. doi: 10.1007/978-3-642-81565-2_15. Recent Results Cancer Res. 1981. PMID: 7232850 No abstract available.
-
Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute.Eur J Cancer (1965). 1981 Feb;17(2):129-42. doi: 10.1016/0014-2964(81)90027-x. Eur J Cancer (1965). 1981. PMID: 6894902 No abstract available.
-
Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions.Adv Pharmacol Chemother. 1984;20:1-20. doi: 10.1016/s1054-3589(08)60263-x. Adv Pharmacol Chemother. 1984. PMID: 6398966 Review. No abstract available.
-
Host-tumor-drug interrelationships in the tumorous murine model.Adv Enzyme Regul. 1980;18:323-34. doi: 10.1016/0065-2571(80)90023-0. Adv Enzyme Regul. 1980. PMID: 7446302 No abstract available.
-
Experimental chemotherapy of human tumors heterotransplanted in nude mice.Antibiot Chemother (1971). 1980;28:21-7. doi: 10.1159/000386055. Antibiot Chemother (1971). 1980. PMID: 6998362 Review.
Cited by
-
Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.Cancer Res. 2016 Oct 1;76(19):5798-5809. doi: 10.1158/0008-5472.CAN-16-0122. Epub 2016 Aug 5. Cancer Res. 2016. PMID: 27496711 Free PMC article.
-
Influence of scheduling on therapeutic and toxic effect of AMSA in Lewis lung carcinoma.Cancer Chemother Pharmacol. 1983;11(1):38-42. doi: 10.1007/BF00257415. Cancer Chemother Pharmacol. 1983. PMID: 6688382
-
Preclinical antitumor activity of batracylin (NSC 320846).Invest New Drugs. 1988 Sep;6(3):147-53. doi: 10.1007/BF00175391. Invest New Drugs. 1988. PMID: 3192381